7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor

The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and...

Full description

Saved in:
Bibliographic Details
Main Authors Ambler, Martin, Paquette, Jay John, Jaquith, James Brian, Osborne, Simon Andrew, Minchinton, Andrew I, Shidmoossavee, Fahimeh S, Smyth, Elliott, Kyle, Alastair H, Smiljanic-Hurley, Ela, Arns, Stephen Paul, Tan, Jason Samuel, Yee, Leanna, Baker, Jennifer H.E, Hamby, Callum, Hsieh, Tom Han Hsiao
Format Patent
LanguageEnglish
Published 25.07.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula.
Bibliography:Application Number: US202218279377